protocolSection identificationModule nctId: NCT06263543, orgStudyIdInfo id: 2023-MAH-001, briefTitle: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC, acronym: SERIES, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Reshma L. Mahtani, D.O., class: OTHER, collaborators name: Gilead Sciences, descriptionModule briefSummary: The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd., conditionsModule conditions: Breast Cancer, conditions: Metastatic Breast Cancer, conditions: Advanced Breast Cancer, conditions: Hormone-receptor-positive Breast Cancer, conditions: Human Epidermal Growth Factor 2 Low Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Sacituzumab govitecan, outcomesModule primaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Clinical benefit rate (CBR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Global Quality of Life, secondaryOutcomes measure: Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs), secondaryOutcomes measure: Laboratory and Vital Sign Abnormalities, secondaryOutcomes measure: Growth Factor Support, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UCLA Jonsson Comprehensive Cancer Center, city: Los Angeles, state: California, zip: 90404, country: United States, contacts name: Aditya Bardia, M.D., role: CONTACT, phone: 310-586-2093, email: ABardia@mednet.ucla.edu, geoPoint lat: 34.05223, lon: -118.24368, locations facility: Miami Cancer Institute at Baptist Health, Inc., city: Miami, state: Florida, zip: 33176, country: United States, contacts name: Reshma L Mahtani, D.O., role: CONTACT, phone: 786-596-2000, email: rmahtani@baptisthealth.net, contacts name: Krystal Fernandez, role: CONTACT, phone: (786) 596-2000, email: krystal.fernandez@baptisthealth.net, geoPoint lat: 25.77427, lon: -80.19366, locations facility: Winship Cancer Institute at Emory University, city: Atlanta, state: Georgia, zip: 30322, country: United States, contacts name: Kevin Kalinsky, M.D., M.S., role: CONTACT, phone: 404-778-0519, email: kkalins@emory.edu, geoPoint lat: 33.749, lon: -84.38798, hasResults: False